ProfileGDS5678 / 1435291_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 86% 87% 91% 91% 89% 89% 89% 90% 89% 88% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1003990
GSM967853U87-EV human glioblastoma xenograft - Control 27.3069690
GSM967854U87-EV human glioblastoma xenograft - Control 37.2668890
GSM967855U87-EV human glioblastoma xenograft - Control 46.7698486
GSM967856U87-EV human glioblastoma xenograft - Control 56.782387
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1166591
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.22491
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9696489
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9526989
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0913189
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1097990
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0347589
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8104188
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0613789